Factors Predicting COVID-19 Vaccine Effectiveness and Longevity of Humoral Immune Responses DOI Creative Commons
Engin Berber, Ted M. Ross

Vaccines, Год журнала: 2024, Номер 12(11), С. 1284 - 1284

Опубликована: Ноя. 15, 2024

The COVID-19 pandemic, caused by SARS-CoV-2, prompted global efforts to develop vaccines control the disease. Various vaccines, including mRNA (BNT162b2, mRNA-1273), adenoviral vector (ChAdOx1, Ad26.COV2.S), and inactivated virus platforms (BBIBP-CorV, CoronaVac), elicit high-titer, protective antibodies against virus, but long-term antibody durability effectiveness vary. objective of this study is elucidate factors that influence vaccine (VE) longevity humoral immune responses through a review relevant literature, clinical real-world studies. Here, we discuss response different identify influencing VE longevity. Despite initial robust responses, vaccine-induced immunity wanes over time, particularly with emergence variants, such as Delta Omicron, exhibit escape mechanisms. Additionally, elicited platforms, along identification essential determinants protection-like pre-existing immunity, booster doses, hybrid demographic factors-are critical for protecting severe COVID-19. Booster vaccinations substantially restore neutralizing levels, especially immune-evasive while individuals have more durable potent response. Importantly, comorbidities diabetes, cardiovascular disease, chronic kidney cancer significantly reduce magnitude protection. Immunocompromised individuals, those undergoing chemotherapy hematologic malignancies, diminished benefit disproportionately from vaccinations. Age sex also older adults experiencing accelerated decline females generally exhibiting stronger compared males. Understanding variables affecting protection crucial improving strategies predicting

Язык: Английский

Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis DOI Creative Commons
Baoqi Zeng, Le Gao, Qingxin Zhou

и другие.

BMC Medicine, Год журнала: 2022, Номер 20(1)

Опубликована: Май 23, 2022

Abstract Background It was urgent and necessary to synthesize the evidence for vaccine effectiveness (VE) against SARS-CoV-2 variants of concern (VOC). We conducted a systematic review meta-analysis provide comprehensive overview profile COVID-19 vaccines VOC. Methods Published randomized controlled trials (RCTs), cohort studies, case-control studies that evaluated VE VOC (Alpha, Beta, Gamma, Delta, or Omicron) were searched until 4 March 2022. Pooled estimates 95% confidence intervals (CIs) calculated using random-effects meta-analysis. defined as (1-estimate). Results Eleven RCTs (161,388 participants), 20 (52,782,321 26 (2,584,732 cases) included. (mRNA-1273, BNT162b2, ChAdOx1, Ad26.COV2.S, NVX-CoV2373, BBV152, CoronaVac, BBIBP-CorV, SCB-2019, CVnCoV, HB02) included in this analysis. Full vaccination effective Alpha, Omicron variants, with 88.0% (95% CI, 83.0–91.5), 73.0% 64.3–79.5), 63.0% 47.9–73.7), 77.8% 72.7–82.0), 55.9% 40.9–67.0), respectively. Booster more Delta 95.5% 94.2–96.5) 80.8% 58.6–91.1), mRNA (mRNA-1273/BNT162b2) seemed have higher over others; significant interactions ( p interaction < 0.10) observed between type (mRNA vs. not vaccines). Conclusions is highly Alpha variant, moderate variants. seem others.

Язык: Английский

Процитировано

239
Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults DOI Open Access
Lianpan Dai,

Lidong Gao,

Lifeng Tao

и другие.

New England Journal of Medicine, Год журнала: 2022, Номер 386(22), С. 2097 - 2111

Опубликована: Май 4, 2022

The ZF2001 vaccine, which contains a dimeric form of the receptor-binding domain severe acute respiratory syndrome coronavirus 2 and aluminum hydroxide as an adjuvant, was shown to be safe, with acceptable side-effect profile, immunogenic in adults phase 1 clinical trials.

Язык: Английский

Процитировано

224
Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2 DOI Open Access
Negar Firouzabadi, Parisa Ghasemiyeh,

Fatemeh Moradishooli

и другие.

International Immunopharmacology, Год журнала: 2023, Номер 117, С. 109968 - 109968

Опубликована: Март 2, 2023

Язык: Английский

Процитировано

77
Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study DOI
Margaux M. I. Meslé,

Jeremy Brown,

Piers Mook

и другие.

The Lancet Respiratory Medicine, Год журнала: 2024, Номер 12(9), С. 714 - 727

Опубликована: Авг. 7, 2024

Язык: Английский

Процитировано

28
SARS-CoV-2’s Variants of Concern: A Brief Characterization DOI Creative Commons

Aline Miranda Scovino,

Elizabeth Chen Dahab, Gustavo Fioravanti Vieira

и другие.

Frontiers in Immunology, Год журнала: 2022, Номер 13

Опубликована: Июль 26, 2022

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disclose the variants of concern (VOC) including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P1), Delta (B.1.617.2), and Omicron (B.1.1.529). Its spike protein (S) present on surface virus is recognized by host cell receptor, angiotensin-2 converting enzyme (ACE2) which promotes their entry into cell. mutations presented VOCs are found in RBD N-terminal region S protein. Therefore, occurring can modify biological immunogenic characteristics virus, such as modifying affinity for ACE2, increasing transmissibility, or conferring ability to escape immune responses. raise a potential new SARS-CoV-2 variant capable evading defenses at same time maintaining its fitness justifies importance continued genetic monitoring pandemic coronavirus.

Язык: Английский

Процитировано

54
The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis DOI Creative Commons

Yuntao Zou,

Doudou Huang,

Qian Jiang

и другие.

Frontiers in Public Health, Год журнала: 2022, Номер 10

Опубликована: Июль 13, 2022

COVID-19 is a respiratory illness caused by SARS-CoV-2. The most recent variant Omicron (line B.1.1.529), which was first identified in South Africa November 2021. concern with this the ineffectiveness of vaccines currently available. We aim to systematically evaluate effectiveness available and boosters for variant.We searched PubMed, Embase, Cochrane Library Web Science databases from inception June 5th, 2022. Studies that examined SARS-CoV-2 against infection were included. Random-effects model used estimate pooled vaccine variant.A total 13 studies included variant, 11 compare between two-dose three-dose (booster) vaccinations. Full vaccination (two-dose or without booster) showed protective effect compared no (OR = 0.62, 95% CI: 0.56-0.69), while decreased significantly over 6 months after last dose. plus booster provided better protection 0.60, 0.52-0.68). Additional analysis performed commonly United Staes: BNT162b2(Pfizer) 0.65, 0.52-0.82) mRNA-1273(Moderna) 0.67, 0.58-0.88) US, similar vaccination.The full dose effectively reduces variant; however, wanes time. provides additional variant.

Язык: Английский

Процитировано

43
Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study) DOI Creative Commons
Zoltán Kiss,

István Wittmann,

Lőrinc Polivka

и другие.

Frontiers in Immunology, Год журнала: 2022, Номер 13

Опубликована: Июнь 23, 2022

In Hungary, the pandemic waves in late 2021 and early 2022 were dominated by Delta Omicron SARS-CoV-2 variants, respectively. Booster vaccines offered with one or two doses for vulnerable population during these periods.

Язык: Английский

Процитировано

41
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial DOI Creative Commons
María Eugenia Toledo-Romaní, Mayra García-Carmenate, Carmen Valenzuela‐Silva

и другие.

The Lancet Regional Health - Americas, Год журнала: 2022, Номер 18, С. 100423 - 100423

Опубликована: Дек. 31, 2022

SOBERANA-02 is a COVID-19 conjugate vaccine (recombinant RBD conjugated to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity, promoting neutralising IgG and specific T-cell response. A third heterologous dose of SOBERANA-Plus (RBD-dimer) further increased antibodies. The aim this study evaluate the safety efficacy two immunisation regimes: doses three-dose combination with added it.From March 8th June 24th, 2021 we conducted in Havana, Cuba multicentre randomised, double-blind, placebo-controlled, phase-3 trial evaluating scheme one it (RPCEC00000354). Participants 19-80 years were randomly assigned receiving 28 days apart either or three placebo. main endpoint was preventing occurrence RT-PCR confirmed symptomatic at least 14 after second per-protocol population. We also assessed against severe disease and, all participants vaccine/placebo dose, for each dose.We included 44,031 (52.0% female, 48.0% male; median age 50 years, range years; 7.0% black, 24.0% mixed-race, 59.0% white) context initial Beta VOC predominance, variant being partially replaced by Delta near trial's end. Vaccine 92.0% (95%CI 80.4-96.7) disease. There no cases group 6 placebo group. Two 69.7% 56.5-78.9) 74.9% 33.7-90.5) efficacious COVID-19, respectively. serious adverse events (AE) very rare equally distributed between groups. Solicited AEs slightly more frequent but predominantly local mostly mild transient.Our results indicate that straightforward manufacture SOBERANA vaccines are circulation, have favourable profile, may represent an attractive option use vaccination programmes.This received funds from National Fund Science Technology (FONCI-CITMA-Cuba, contract 2020-20) Ministry Science, Environment Cuba.

Язык: Английский

Процитировано

39
Antibody responses to COVID‐19 vaccination in people with obesity: A systematic review and meta‐analysis DOI Creative Commons

Xiaodan Ou,

Jialin Jiang,

Bingqian Lin

и другие.

Influenza and Other Respiratory Viruses, Год журнала: 2022, Номер 17(1)

Опубликована: Дек. 19, 2022

COVID-19 vaccine is critical in preventing SARS-CoV-2 infection and transmission. However, obesity's effect on immune responses to vaccines still unknown. We performed a meta-analysis of the literature compared antibody with among persons without obesity. used Pubmed, Embase, Web Science, Cochrane Library identify all related studies up April 2022. The Stata.14 software was analyze selected data. Eleven were included present meta-analysis. Five them provided absolute values titers obese group non-obese group. Overall, we found that population significantly associated lower (standardized mean difference [SMD] = -0.228, 95% CI [-0.437, -0.019], P < 0.001) after vaccination. Significant heterogeneity most pooled analyses but reduced subgroup analyses. No publication bias observed analysis. Trim Fill method did not change results primary suggested obesity decreased vaccines. Future should be unravel mechanism response individuals.

Язык: Английский

Процитировано

33
Herpesviruses reactivation following COVID-19 vaccination: a systematic review and meta-analysis DOI Creative Commons
Arman Shafiee, Mohammad Javad Amini, Razman Arabzadeh Bahri

и другие.

European journal of medical research, Год журнала: 2023, Номер 28(1)

Опубликована: Авг. 10, 2023

Abstract Background The reactivation of herpesviruses (HHV) in COVID-19 patients is evident the literature. Several reports have been published regarding these viruses (HSV, VZV, EBV, and CMV) among those who got vaccines. In this study, we aimed to review current evidence assess whether HHVs has any association with prior administration Methods A systematic search was conducted on 25 September 2022 PubMed/MEDLINE, Web Science, EMBASE. We included all observational studies, case reports, series which reported human following Results Our showed 80 articles that meet eligibility criteria. Among evaluated vaccines, most vaccines were mRNA based. Evidence from studies possible relation between vaccine VZV HSV reactivation. results our proportion meta-analysis rate received 14 persons per 1000 vaccinations (95% CI 2.97–32.80). Moreover, for 16 1.06–46.4). Furthermore, reports/series 149 cases HHV There several caused including BNT162b2 or Pfizer–BioNTech ( n = 76), Oxford-AstraZeneca 22), mRNA-1273 Moderna 17), Sinovac 4), BBIBP-CorV Sinopharm 3), Covaxin Covishield Johnson 1). Reactivated varicella-zoster virus (VZV) 114), cytomegalovirus (CMV) 15), herpes simplex (HSV) 14), Epstein-Barr (EBV) 6), HHV-6 2). Most their disease after first dose vaccine. Many having comorbidities, hypertension, diabetes mellitus, dyslipidemia, chicken pox, atrial fibrillation common. Conclusion conclusion, study vaccination herpesvirus supported by studies. However, other (EBV CMV), further research especially clinical trials required elucidate interaction

Язык: Английский

Процитировано

17